Amicus Therapeutics Announces FDA Approval and Launch of
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...
Source: globenewswire.com
📰 Team Amicu News
Team Amicu News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Team Amicu. Real-time updates on events, politics, business and more.
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Pombiliti™ + Opfolda™ Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference...
Source: marketscreener.com